These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 15090062)

  • 1. Expectation of caffeine induces dopaminergic responses in humans.
    Kaasinen V; Aalto S; Någren K; Rinne JO
    Eur J Neurosci; 2004 Apr; 19(8):2352-6. PubMed ID: 15090062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of repetitive transcranial magnetic stimulation on [11C]raclopride binding and cognitive function in patients with depression.
    Kuroda Y; Motohashi N; Ito H; Ito S; Takano A; Nishikawa T; Suhara T
    J Affect Disord; 2006 Oct; 95(1-3):35-42. PubMed ID: 16781779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral D-amphetamine causes prolonged displacement of [11C]raclopride as measured by PET.
    Cárdenas L; Houle S; Kapur S; Busto UE
    Synapse; 2004 Jan; 51(1):27-31. PubMed ID: 14579423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic effects of caffeine in the human striatum and thalamus.
    Kaasinen V; Aalto S; Någren K; Rinne JO
    Neuroreport; 2004 Feb; 15(2):281-5. PubMed ID: 15076753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of monoamine oxidase inhibition on amphetamine-evoked changes in dopamine receptor availability in the living pig: a dual tracer PET study with [11C]harmine and [11C]raclopride.
    Jensen SB; Olsen AK; Pedersen K; Cumming P
    Synapse; 2006 Jun; 59(7):427-34. PubMed ID: 16485265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study.
    Thobois S; Vingerhoets F; Fraix V; Xie-Brustolin J; Mollion H; Costes N; Mertens P; Benabid AL; Pollak P; Broussolle E
    Arch Neurol; 2004 Nov; 61(11):1705-9. PubMed ID: 15534182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of striatal dopamine D2/D3 receptor binding potential with pain but not tactile sensitivity or placebo analgesia.
    Martikainen IK; Hagelberg N; Mansikka H; Hietala J; Någren K; Scheinin H; Pertovaara A
    Neurosci Lett; 2005 Mar; 376(3):149-53. PubMed ID: 15721212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intravenous placebo with glucose expectation on human basal ganglia dopaminergic function.
    Haltia LT; Rinne JO; Helin S; Parkkola R; Någren K; Kaasinen V
    Synapse; 2008 Sep; 62(9):682-8. PubMed ID: 18566972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of expectation on placebo-induced dopamine release in Parkinson disease.
    Lidstone SC; Schulzer M; Dinelle K; Mak E; Sossi V; Ruth TJ; de la Fuente-Fernández R; Phillips AG; Stoessl AJ
    Arch Gen Psychiatry; 2010 Aug; 67(8):857-65. PubMed ID: 20679593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation.
    Strafella AP; Ko JH; Monchi O
    Neuroimage; 2006 Jul; 31(4):1666-72. PubMed ID: 16545582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease.
    de la Fuente-Fernández R; Ruth TJ; Sossi V; Schulzer M; Calne DB; Stoessl AJ
    Science; 2001 Aug; 293(5532):1164-6. PubMed ID: 11498597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study.
    Sossi V; de la Fuente-Fernández R; Schulzer M; Troiano AR; Ruth TJ; Stoessl AJ
    Ann Neurol; 2007 Nov; 62(5):468-74. PubMed ID: 17886297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of the placebo effect and of conditioning.
    Haour F
    Neuroimmunomodulation; 2005; 12(4):195-200. PubMed ID: 15990450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity.
    Jucaite A; Fernell E; Halldin C; Forssberg H; Farde L
    Biol Psychiatry; 2005 Feb; 57(3):229-38. PubMed ID: 15691523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of intravenous glucose on dopaminergic function in the human brain in vivo.
    Haltia LT; Rinne JO; Merisaari H; Maguire RP; Savontaus E; Helin S; Någren K; Kaasinen V
    Synapse; 2007 Sep; 61(9):748-56. PubMed ID: 17568412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users.
    Shi J; Zhao LY; Copersino ML; Fang YX; Chen Y; Tian J; Deng Y; Shuai Y; Jin J; Lu L
    Eur J Pharmacol; 2008 Jan; 579(1-3):160-6. PubMed ID: 17977528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis.
    Lee CS; Schulzer M; de la Fuente-Fernández R; Mak E; Kuramoto L; Sossi V; Ruth TJ; Calne DB; Stoessl AJ
    Arch Neurol; 2004 Dec; 61(12):1920-5. PubMed ID: 15596613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanisms of placebo effect and of conditioning: neurobiological data in human and animals].
    Haour F
    Med Sci (Paris); 2005 Mar; 21(3):315-9. PubMed ID: 15745708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions.
    Murray D; Stoessl AJ
    Pharmacol Ther; 2013 Dec; 140(3):306-18. PubMed ID: 23880289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The placebo effect in Parkinson's disease.
    de la Fuente-Fernández R; Stoessl AJ
    Trends Neurosci; 2002 Jun; 25(6):302-6. PubMed ID: 12086748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.